Amod Sarnaik, MD, on Lifileucel’s Place in the Treatment Lanscape for Advanced Melanoma

Video

Sarnaik discussed the investigational TIL therapy’s potential as an additional option for patients.

“There are definitely challenges associated with implementation of a product as complex as lifileucel. This requires mobilization of resources that as a medical field we're not quite used to. The treatment does involve extensive patient and caregiver education, as well as mobilization of resources associated with practitioners of surgical oncology, medical oncology, as well as cellular therapy. Of note, cellular therapy is still a relatively emerging field, and therefore represents a relatively scarce resource.”

While there are various treatments available for patients with advanced melanoma, many of these treatments have substantial limitations or drawbacks, leaving some patients with few viable options. In this situation, some patients will turn to investigational therapies being evaluated in clinical trials.

Amod A. Sarnaik, MD, FACS, Moffitt Cancer Center and University of South Florida, recently presented data from the phase 2 C-144-01 (NCT02360579) clinical trial evaluating lifileucel (LN-144), an investigational autologous tumor infiltrating lymphocyte (TIL) therapy, at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting, November 8-12, 2022, in Boston, Massachusetts.

In an interview with CGTLive, Sarnaik discussed the current treatment landscape for advanced melanoma, going over the various options available and their respective limitations, and then gave his view on where lifileucel could fit into this landscape if it becomes an approved therapy. He also discussed some of the challenges of implementing lifileucel in the clinic, going over the infrastructural limitations that currently make cell therapy options less accessible for patients than more conventional treatments.

Recent Videos
Robert Califf, MD, MACC, a cardiologist and former FDA commissioner
Natalie Goedeker, CPNP, on Handling Neuromuscular Gene Therapy at Real-World Sites
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
Michael Flanagan, PhD, chief scientific officer at Avidity
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Related Content
© 2025 MJH Life Sciences

All rights reserved.